mln9708
T-cell Adult Acute Lymphoblastic Leukemia
Massachusetts General HospitalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the T-cell Adult Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Monomethyl Fumarate Case Comprehensive Cancer Center | Phase 2 | B |
Busulphan Case Comprehensive Cancer Center | Phase 2 | B |
CYCLOSPORIN A Case Comprehensive Cancer Center | Phase 2 | B |
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | B |
View all 19 →
Same molecule, other indications
mln9708 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →